GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intec Parent Inc (NAS:NTEC) » Definitions » ROE %

Intec Parent (Intec Parent) ROE % : -130.74% (As of Mar. 2021)


View and export this data going back to 1996. Start your Free Trial

What is Intec Parent ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Intec Parent's annualized net income for the quarter that ended in Mar. 2021 was $-16.92 Mil. Intec Parent's average Total Stockholders Equity over the quarter that ended in Mar. 2021 was $12.94 Mil. Therefore, Intec Parent's annualized ROE % for the quarter that ended in Mar. 2021 was -130.74%.

The historical rank and industry rank for Intec Parent's ROE % or its related term are showing as below:

NTEC's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -44.1
* Ranked among companies with meaningful ROE % only.

Intec Parent ROE % Historical Data

The historical data trend for Intec Parent's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intec Parent ROE % Chart

Intec Parent Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
ROE %
Get a 7-Day Free Trial -45.89 -70.94 -77.52 -146.28 -108.39

Intec Parent Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -120.21 -77.56 -87.34 -87.61 -130.74

Competitive Comparison of Intec Parent's ROE %

For the Biotechnology subindustry, Intec Parent's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intec Parent's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intec Parent's ROE % distribution charts can be found below:

* The bar in red indicates where Intec Parent's ROE % falls into.



Intec Parent ROE % Calculation

Intec Parent's annualized ROE % for the fiscal year that ended in Dec. 2020 is calculated as

ROE %=Net Income (A: Dec. 2020 )/( (Total Stockholders Equity (A: Dec. 2019 )+Total Stockholders Equity (A: Dec. 2020 ))/ count )
=-14.128/( (11.535+14.533)/ 2 )
=-14.128/13.034
=-108.39 %

Intec Parent's annualized ROE % for the quarter that ended in Mar. 2021 is calculated as

ROE %=Net Income (Q: Mar. 2021 )/( (Total Stockholders Equity (Q: Dec. 2020 )+Total Stockholders Equity (Q: Mar. 2021 ))/ count )
=-16.916/( (14.533+11.344)/ 2 )
=-16.916/12.9385
=-130.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2021) net income data. ROE % is displayed in the 30-year financial page.


Intec Parent  (NAS:NTEC) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2021 )
=Net Income/Total Stockholders Equity
=-16.916/12.9385
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-16.916 / 0)*(0 / 19.163)*(19.163 / 12.9385)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.4811
=ROA %*Equity Multiplier
=N/A %*1.4811
=-130.74 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2021 )
=Net Income/Total Stockholders Equity
=-16.916/12.9385
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-16.916 / -16.836) * (-16.836 / -16.712) * (-16.712 / 0) * (0 / 19.163) * (19.163 / 12.9385)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0048 * 1.0074 * N/A % * 0 * 1.4811
=-130.74 %

Note: The net income data used here is four times the quarterly (Mar. 2021) net income data. The Revenue data used here is four times the quarterly (Mar. 2021) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Intec Parent ROE % Related Terms

Thank you for viewing the detailed overview of Intec Parent's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Intec Parent (Intec Parent) Business Description

Traded in Other Exchanges
N/A
Address
12 Hartom Street, Har Hotzvim, Jerusalem, ISR, 9777512
Intec Parent Inc, formerly Intec Pharma Ltd is a clinical-stage biopharmaceutical company based in Israel. The company is focused on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. Accordion Pill Carbidopa/Levodopa or AP-CDLD is being developed by the company for the indication of treatment of Parkinson's disease.
Executives
Walt Addison Linscott officer: Chief Business Officer 1860 MONTREAL ROAD, TUCKER GA 30084
Nir Sassi officer: Chief Financial Officer 3 ELUL STREET, APT. 6, MODIIN L3 7176397
Nadav Navon officer: Chief Operating Officer 18 LEA IMENU STREET MODIIN L3 7177945
Anthony J Maddaluna director PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
William B Hayes director 231 MAPLE AVENUE, BURLINGTON NC 27215
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Hila Karah director 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
John W Kozarich director 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121
Jeffrey A Meckler director, officer: Chief Executive Officer 740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
R Michael Gendreau officer: Chief Medical Officer 4350 EXECUTIVE DRIVE SUITE 325 SAN DIEGO CA 92121
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 3060000
Dan Oren 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 30600000
Gil Bianco director 7 HAORANIM STREET BAZRA L3 60944